The story of Viagra presents a intricate picture for shareholders. While the initial release generated significant profits, the end of its exclusive rights opened the floodgates to cheaper alternatives, dramatically reducing market share. This presents a unique dilemma for firms banking on comparable blockbuster products, suggesting that a careless

The story of Viagra, and its creator copyright, presents a intriguing case study for investors. At first a blockbuster drug, generating billions in sales , its exclusivity period created a flood of knock-off medications, significantly eroding its market share . While some firms may attempt to capitalize on similar conditions , the current landscape